US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Braveheart Bio

27.25

-1.6600-5.74%

Post-market: 26.72-0.5300-1.94%17:23 EDT

Volume:286.00K

Turnover:7.92M

Market Cap:2.45B

PE:-10.35

High:29.50

Open:28.94

Low:26.47

Close:28.91

52wk High:32.00

52wk Low:24.31

Shares:90.04M

Float Shares:25.83M

Volume Ratio:0.75

T/O Rate:1.11%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.6319

EPS(LYR):-3.9270

ROE:--

ROA:--

PB:-31.30

PE(LYR):-6.94

Loading ...

Overview Company News Filings

Goldman Sachs Remains a Buy on Braveheart Bio, Inc. (BRVE)

Analysts Offer Insights on NA Companies: IMAX (IMAX) and Braveheart Bio, Inc. (BRVE)

Braveheart Bio Q2 EPS $(2.51)

Benzinga Earnings

Earnings Flash (BRVE) Braveheart Bio Posts Q2 Loss $2.51 per Share

MT Newswires Live

Braveheart Bio Q2 FY26 Net Loss Widens to $15 Million; R&D Expenses Rise to $11.1 Million

Braveheart Bio, - Q2 Net Loss Attributable to Common Stockholders was $18.60 Mln or $2.51 Per Share

THOMSON REUTERS

Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

THOMSON REUTERS

Analysts Offer Insights on NA Companies: Braveheart Bio, Inc. (BRVE) and TeraWulf Inc (WULF)

Braveheart Bio to Participate in Cantor Global Healthcare Conference

Braveheart Bio Initiated at Buy by Stifel

Cantor Fitzgerald Initiates Braveheart Bio at Overweight With $40 Price Target

MT Newswires Live

Stifel Initiates Braveheart Bio at Buy With $45 Price Target

MT Newswires Live

Braveheart Bio, Inc. : TD Cowen Initiates Coverage with Buy Rating

THOMSON REUTERS

Braveheart Bio initiated with a Buy at Jefferies

Braveheart Bio initiated with a Buy at Goldman Sachs

U.S. Research Roundup-Adobe, Braveheart Bio, CACI International

TipRanks Analyst Salveen Richter Reiterates Buy on Braveheart Bio, Sets $48 12-Month Target on Strong HCM Opportunity for Lead Asset BHB-1893

Braveheart Bio Director Vineeta Agarwala Files Initial Beneficial Ownership Statement

Insiders Double Down on Braveheart Bio in Massive Confidence Play

OrbiMed Advisors Acquires 1.940.000 Braveheart Bio Common Shares Worth $ 34,92 Juta

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrzen.com/stock/BRVE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BRVE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BRVE\",,,,,undefined,":{"symbol":"BRVE","market":"US","secType":"STK","nameCN":"Braveheart Bio","latestPrice":27.25,"timestamp":1789070400000,"preClose":28.91,"halted":0,"volume":285996,"hourTrading":{"tag":"盘后","latestPrice":26.72,"preClose":27.25,"latestTime":"17:23 EDT","volume":4206,"amount":114610.85022,"timestamp":1789075385634,"change":-0.53,"changeRate":-0.01945,"amplitude":0.01945},"delay":0,"changeRate":-0.05741957800069181,"floatShares":25831738,"shares":90039000,"eps":-2.631887,"marketStatus":"Post-Mkt","change":-1.66,"latestTime":"09-10 19:07:43 EDT","open":28.94,"high":29.5,"low":26.47,"amount":7918397.563632,"amplitude":0.104808,"askPrice":27.78,"askSize":72,"bidPrice":26.72,"bidSize":75,"shortable":3,"etf":0,"ttmEps":-2.631887,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789084800000},"marketStatusCode":4,"adr":0,"listingDate":1785988800000,"exchange":"NASDAQ","adjPreClose":28.91,"postHourTrading":{"tag":"盘后","latestPrice":26.72,"preClose":27.25,"latestTime":"17:23 EDT","volume":4206,"amount":114610.85022,"timestamp":1789075385634,"change":-0.53,"changeRate":-0.01945,"amplitude":0.01945},"volumeRatio":0.745858},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BRVE\",,,,,undefined,":{"symbol":"BRVE","floatShares":25831738,"roa":"--","roe":"--","lyrEps":-3.927011,"volumeRatio":0.745858,"shares":90039000,"dividePrice":0,"high":29.5,"amplitude":0.104808,"preClose":28.91,"low":26.47,"week52Low":24.305,"pbRate":"-31.30","week52High":32,"institutionHeld":0,"latestPrice":27.25,"committee":0.020408,"eps":-2.631887,"divideRate":0,"volume":285996,"delay":0,"ttmEps":-2.631887,"open":28.94,"prevYearClose":18,"prevWeekClose":26.74,"prevMonthClose":25.5,"prevQuarterClose":18,"fiveDayClose":26.95,"twentyDayClose":26.15,"sixtyDayClose":18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BRVE\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BRVE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BRVE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":4,"updateTime":1788926400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BRVE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BRVE","date":"2026-09-09","current":-10.353788,"percent":0.041667,"low":-23.993466,"twenty":-22.21795,"median":-21.930028,"eighty":-20.885512,"high":-12.297967,"avg":-21.137744,"sd":2.55445,"marketCap":1887208084},"quantilePoints":[{"date":"2026-08-07","current":-22.904964,"twenty":-19.277064,"median":-13.835213,"eighty":-12.912865,"marketCap":1837733965},{"date":"2026-08-14","current":-20.770344,"twenty":-22.55018,"median":-20.842324,"eighty":-16.302149,"marketCap":1666466982},{"date":"2026-08-21","current":-21.930028,"twenty":-22.591769,"median":-21.618113,"eighty":-20.309669,"marketCap":1759511923},{"date":"2026-08-28","current":-22.281932,"twenty":-22.249941,"median":-22.006007,"eighty":-20.827928,"marketCap":1787746250},{"date":"2026-09-04","current":-21.010278,"twenty":-22.169963,"median":-21.930028,"eighty":-20.827928,"marketCap":1685717659},{"date":"2026-09-09","current":-23.521594,"twenty":-22.21795,"median":-21.930028,"eighty":-20.885512,"marketCap":1887208084}],"updateTime":1789081663947},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BRVE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666538872","title":"Goldman Sachs Remains a Buy on Braveheart Bio, Inc. (BRVE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538872","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538872?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:55","pubTimestamp":1788954946,"startTime":"0","endTime":"0","summary":"Goldman Sachs analyst Salveen Richter maintained a Buy rating on Braveheart Bio, Inc. yesterday and set a price target of $48.00. The company’s sha...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/goldman-sachs-remains-a-buy-on-braveheart-bio-inc-brve-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/goldman-sachs-remains-a-buy-on-braveheart-bio-inc-brve-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0251142724.SGD","BK4007","BK4550","LU2237443549.SGD","LU2237443895.HKD","LU0868494617.USD","LU0942090050.USD","BK4588","LU1804176565.USD","IE00BFXG1179.USD","LU1894683264.USD","LU1868837136.USD","LU0345770993.USD","IE00B19Z3581.USD","LU1868836591.USD","GSX","IE0004091025.USD","LU2237438978.USD","LU0096364046.USD","BRVE","LU2237443622.USD","IE0034235188.USD","LU2471134523.USD","LU2265009873.SGD","LU0048573561.USD","LU0061475181.USD","IE0004086264.USD","LU2750360997.AUD","LU2237443978.SGD","LU1868836914.USD","LU1868836757.USD","LU2896262040.SGD","LU0742534661.SGD","LU2750360641.GBP","LU2237443382.USD","BK4552","LU1894683348.USD","LU0251131958.USD","BK4533","LU0345770308.USD","LU1144417596.USD","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","LU2471134879.HKD","LU2471134952.CNY","LU1668664300.SGD","BK4504","LU1791807156.HKD","BK4127","LU0210536198.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587784","title":"Analysts Offer Insights on NA Companies: IMAX (IMAX) and Braveheart Bio, Inc. (BRVE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587784","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666587784?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:10","pubTimestamp":1788952247,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on IMAX (IMAX) and Braveheart Bio, Inc. (BRVE) with bullish sen...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-imax-imax-and-braveheart-bio-inc-brve-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-imax-imax-and-braveheart-bio-inc-brve-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4141","NA","IMAX","BK4007","BRVE","BK4108"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377403","title":"Braveheart Bio Q2 EPS $(2.51)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377403","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377403?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:37","pubTimestamp":1788899876,"startTime":"0","endTime":"0","summary":"Braveheart Bio (NASDAQ:BRVE) reported quarterly losses of $(2.51) per share which missed the analyst consensus estimate of $0.74 by 439.19 percent. This is a 1692.86 percent decrease over losses of $(0.14) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/09/61673604/braveheart-bio-q2-eps-2-51","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Braveheart Bio Q2 EPS $(2.51)","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666773503","title":"Earnings Flash (BRVE) Braveheart Bio Posts Q2 Loss $2.51 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2666773503","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666773503?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:13","pubTimestamp":1788898431,"startTime":"0","endTime":"0","summary":"Earnings Flash (BRVE) Braveheart Bio Posts Q2 Loss $2.51 per Share","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666854377","title":"Braveheart Bio Q2 FY26 Net Loss Widens to $15 Million; R&D Expenses Rise to $11.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2666854377","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666854377?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:08","pubTimestamp":1788898095,"startTime":"0","endTime":"0","summary":"Braveheart Bio Q2 FY26 net loss widens to $15 million; R&D expenses rise to $11.1 millionBraveheart Bio posted a Q2 net loss of $15 million, versus a $0.4 million loss a year earlier.Net loss attribut","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL8kvcjS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377601","title":"Braveheart Bio, - Q2 Net Loss Attributable to Common Stockholders was $18.60 Mln or $2.51 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377601","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377601?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:03","pubTimestamp":1788897781,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA1VZYZG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666372798","title":"Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2666372798","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666372798?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:03","pubTimestamp":1788897781,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA1VZYZG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665901263","title":"Analysts Offer Insights on NA Companies: Braveheart Bio, Inc. (BRVE) and TeraWulf Inc (WULF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665901263","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665901263?lang=en_us&edition=fundamental","pubTime":"2026-09-07 16:10","pubTimestamp":1788768608,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Braveheart Bio, Inc. (BRVE) and TeraWulf Inc (WULF) with bul...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-braveheart-bio-inc-brve-and-terawulf-inc-wulf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-braveheart-bio-inc-brve-and-terawulf-inc-wulf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4595","NA","BK4141","FDIG","BK4007","WULX","BK4600","BRVE","WULF","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664086926","title":"Braveheart Bio to Participate in Cantor Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664086926","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664086926?lang=en_us&edition=fundamental","pubTime":"2026-09-02 04:30","pubTimestamp":1788294600,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, Sept.  01, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3354630/0/en/braveheart-bio-to-participate-in-cantor-global-healthcare-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0203345920.USD","LU0472753341.HKD","LU0203347892.USD","BK4531","BK4007","BK4585","XBI","BK4567","LU0069063385.USD","BK4588","LU0128526141.USD","LU0124676726.USD","BK4581","LU0057025933.USD","BK4533","LU0289961442.SGD","BK4149","LU0689626769.HKD","MADE","LU0029874061.USD","LU0154245673.USD","LU0154245756.USD","LU0289739343.SGD","IE000M9KFDE8.USD","LABU","CMI","BK4137","LU2463526074.USD","BRVE","HCM","HCSG","LU0511384066.AUD","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663072364","title":"Braveheart Bio Initiated at Buy by Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2663072364","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663072364?lang=en_us&edition=fundamental","pubTime":"2026-08-31 18:36","pubTimestamp":1788172560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BRVE/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRVE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663224074","title":"Cantor Fitzgerald Initiates Braveheart Bio at Overweight With $40 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2663224074","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663224074?lang=en_us&edition=fundamental","pubTime":"2026-08-31 18:32","pubTimestamp":1788172345,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald Initiates Braveheart Bio at Overweight With $40 Price Target","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663718150","title":"Stifel Initiates Braveheart Bio at Buy With $45 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2663718150","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663718150?lang=en_us&edition=fundamental","pubTime":"2026-08-31 17:49","pubTimestamp":1788169786,"startTime":"0","endTime":"0","summary":"Stifel Initiates Braveheart Bio at Buy With $45 Price Target","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663079570","title":"Braveheart Bio, Inc. : TD Cowen Initiates Coverage with Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2663079570","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663079570?lang=en_us&edition=fundamental","pubTime":"2026-08-31 17:38","pubTimestamp":1788169103,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S05T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663076785","title":"Braveheart Bio initiated with a Buy at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2663076785","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663076785?lang=en_us&edition=fundamental","pubTime":"2026-08-31 17:06","pubTimestamp":1788167163,"startTime":"0","endTime":"0","summary":"Jefferies initiated coverage of Braveheart Bio (BRVE) with a Buy rating and $48 price target The two Phase II datasets from the company’s China par...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/braveheart-bio-initiated-with-a-buy-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/braveheart-bio-initiated-with-a-buy-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BRVE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663341075","title":"Braveheart Bio initiated with a Buy at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2663341075","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663341075?lang=en_us&edition=fundamental","pubTime":"2026-08-31 16:35","pubTimestamp":1788165310,"startTime":"0","endTime":"0","summary":"Goldman Sachs analyst Salveen Richter initiated coverage of Braveheart Bio (BRVE) with a Buy rating and $48 price target Braveheart is a clinical-s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/braveheart-bio-initiated-with-a-buy-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/braveheart-bio-initiated-with-a-buy-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0004091025.USD","BK4007","LU2237443895.HKD","LU0096364046.USD","LU1144417596.USD","BK4552","LU0742534661.SGD","LU2237443382.USD","LU2237443978.SGD","BK4516","LU0868494708.USD","BK4127","IE00BSNM7G36.USD","BRVE","LU1668664300.SGD","LU1868837136.USD","LU1894683264.USD","IE0004086264.USD","LU2750360641.GBP","LU0345770308.USD","LU2237443549.SGD","LU1804176565.USD","IE00BFXG1179.USD","LU0345770993.USD","LU2265009873.SGD","LU0942090050.USD","LU0210536198.USD","LU2237438978.USD","BK4588","LU1894683348.USD","LU2896262040.SGD","IE0034235188.USD","LU0251142724.SGD","LU2750360997.AUD","LU1868836591.USD","LU0048573561.USD","LU0061475181.USD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","GSX","LU1868836757.USD","LU2471134952.CNY","LU2471134523.USD","LU2471134796.USD","LU1868836914.USD","BK4504","LU1791807156.HKD","BK4533","LU0106831901.USD","LU2471134879.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663020059","title":"U.S. Research Roundup-Adobe, Braveheart Bio, CACI International","url":"https://stock-news.laohu8.com/highlight/detail?id=2663020059","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663020059?lang=en_us&edition=fundamental","pubTime":"2026-08-31 15:24","pubTimestamp":1788161046,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Adobe, Braveheart Bio, CACI InternationalAug 31 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adob","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL4N44S0J8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KALU","IBM","BAC","RBRK","FIVN","BCDF","XTL","DE","HWAY","HQY","SCTX","PCG","RKLB","ATTO","DLTR","TROW","PYPL","ETR","BRVE","ASST","CRM","FTAG","LUNR","CACI","BPOP","ADBE","BURL","RDW","SBRA","BILT","CIEN","TPZ","AFRM","ADSK","MADE","BW","SRE","RVMD","ANF","PTGX","PATH","OHI","HONA","AIRJ","ICE","ATI","AFRU","BRCC","MDB","EIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663027370","title":"TipRanks Analyst Salveen Richter Reiterates Buy on Braveheart Bio, Sets $48 12-Month Target on Strong HCM Opportunity for Lead Asset BHB-1893","url":"https://stock-news.laohu8.com/highlight/detail?id=2663027370","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663027370?lang=en_us&edition=fundamental","pubTime":"2026-08-31 14:16","pubTimestamp":1788156960,"startTime":"0","endTime":"0","summary":"Braveheart Bio, Inc. (BRVE) has received a new Buy rating, initiated by Goldman Sachs analyst, Salveen Richter. Salveen Richter has given his Buy r...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/tipranks-analyst-salveen-richter-reiterates-buy-on-braveheart-bio-sets-48-12-month-target-on-strong-hcm-opportunity-for-lead-asset-bhb-1893-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/tipranks-analyst-salveen-richter-reiterates-buy-on-braveheart-bio-sets-48-12-month-target-on-strong-hcm-opportunity-for-lead-asset-bhb-1893-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0942090050.USD","LU2471134952.CNY","IE0002270589.USD","LU0868494617.USD","LU2237438978.USD","LU0345770308.USD","LU0106831901.USD","BK4127","LU1894683348.USD","LU0096364046.USD","LU2237443622.USD","LU0251131958.USD","IE0004086264.USD","LU1868836591.USD","BK4504","BRVE","GSX","LU2896262040.SGD","BK4211","BK4533","LU1668664300.SGD","IE0004091025.USD","LU2237443549.SGD","LU0868494708.USD","LU0061475181.USD","IE00B19Z3B42.SGD","LU1868836914.USD","LU2471134879.HKD","BK4552","LU1868836757.USD","LU2237443382.USD","LU2471134796.USD","LU2750360997.AUD","LU0251142724.SGD","LU2265009873.SGD","LU1791807156.HKD","IE0034235188.USD","BK4585","BK4516","LU2237443895.HKD","BK4550","LU0210536198.USD","BK4588","LU1868837300.USD","IE00BFXG1179.USD","BHB","LU1868837136.USD","DBB","LU2750360641.GBP","LU1804176565.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659243121","title":"Braveheart Bio Director Vineeta Agarwala Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2659243121","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659243121?lang=en_us&edition=fundamental","pubTime":"2026-08-15 05:05","pubTimestamp":1786741522,"startTime":"0","endTime":"0","summary":"Braveheart Bio director Vineeta Agarwala files initial beneficial ownership statementDirector Vineeta Agarwala filed an initial Form 3 for Braveheart Bio, reporting indirect ownership of 10,232,420 co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL4ChQML:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658947790","title":"Insiders Double Down on Braveheart Bio in Massive Confidence Play","url":"https://stock-news.laohu8.com/highlight/detail?id=2658947790","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658947790?lang=en_us&edition=fundamental","pubTime":"2026-08-12 10:01","pubTimestamp":1786500109,"startTime":"0","endTime":"0","summary":"New insider activity at Braveheart Bio, Inc. ( ($BRVE) ) has taken place on August 11, 2026. Braveheart Bio, Inc. has attracted substantial insider...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/insiders-double-down-on-braveheart-bio-in-massive-confidence-play-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/insiders-double-down-on-braveheart-bio-in-massive-confidence-play-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658494615","title":"OrbiMed Advisors Acquires 1.940.000 Braveheart Bio Common Shares Worth $ 34,92 Juta","url":"https://stock-news.laohu8.com/highlight/detail?id=2658494615","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658494615?lang=en_us&edition=fundamental","pubTime":"2026-08-12 05:28","pubTimestamp":1786483716,"startTime":"0","endTime":"0","summary":"OrbiMed Advisors acquires 1.940.000 Braveheart Bio common shares worth $ 34,92 jutaBraveheart Bio melaporkan OrbiMed Advisors meningkatkan kepemilikan tidak langsung menjadi 11.901.826 saham biasa.Pos","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL8hq9sF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"OrbiMed Advisors Acquires 1.940.000 Braveheart Bio Common Shares Worth $ 34,92 Juta","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":34,"code":"91000000","status":"200"}]}}